Evidence map›Paper›PMID 30354813›Full record

ArticleHypertension (Dallas, Tex. : 1979)2018

Klotho Ameliorates Medullary Fibrosis and Pressure Natriuresis in Hypertensive Rat Kidneys.

Tsuneo Takenaka, Tsutomu Inoue, Takashi Miyazaki, Hiroyuki Kobori, Akira Nishiyama, Naohito Ishii, Matsuhiko Hayashi, Hiromichi Suzuki

Open access · bronzeAbstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Oxidative Stress in Kidney Injury and Hypertension.Antioxidants (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Low Serum Klotho Associated With All-cause Mortality Among a Nationally Representative Sample of American Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Tsuneo TakenakaFrom the Department of Medicine, International University of Health and Welfare, Minato, Tokyo, Japan (T.T., H.K.).
Tsutomu InoueDepartment of Nephrology, Saitama Medical University, Iruma, Japan (T.I., T.M., H.S.).
Takashi MiyazakiDepartment of Nephrology, Saitama Medical University, Iruma, Japan (T.I., T.M., H.S.).
Hiroyuki KoboriFrom the Department of Medicine, International University of Health and Welfare, Minato, Tokyo, Japan (T.T., H.K.).
Akira NishiyamaDepartment of Pharmacology, Kagawa University, Kita, Japan (A.N.).
Naohito IshiiDepartment of Clinical Chemistry, Kitasato University, Sagamihara, Kanagawa, Japan (N.I.).
Matsuhiko HayashiBlood Purification Center, Keio University, Shinjuku, Tokyo, Japan (M.H.).
Hiromichi SuzukiDepartment of Nephrology, Saitama Medical University, Iruma, Japan (T.I., T.M., H.S.).
International University of Health and Welfare · JPSaitama Medical University · JPKagawa University · JPKitasato University · JPSuzuki (Japan) · JP

Funding

Intrarenal Augmentation of Angiotensinogen by Ang IIR01DK072408 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI NAVAR, LUIS GABRIEL · 2006 to 2010
$1.2M
NIDDK NIH HHS R01 DK072408
6 · The paper itself

Abstract

Renal expression of klotho is reduced in hypertension. Experiments were performed to examine whether exogenous klotho protein supplementation ameliorates pressure natriuresis in early phase of hypertension, using stroke-prone spontaneously hypertensive rats (sp-SHR). The interactions between klotho protein and renal renin-Ang (angiotensin) system were examined with immunoprecipitation and cell culture methods. Uninephrectomy was performed in sp-SHRs to induce nephrosclerosis, and they were treated with exogenous klotho protein or vehicle. Exogenous klotho protein supplementation to sp-SHR decreased blood pressure, renal Ang II levels, AGT (angiotensinogen) expression, HIF (hypoxia-inducible factor)-1α abundance, and medullary fibronectin levels, with increased renal klotho expression and serum and urine klotho levels. Klotho supplementation also reduced kidney weight, renal phosphorylated Akt, and mTOR (mammalian target of rapamycin) abundance. Furthermore, klotho supplementation restored renal autoregulation of glomerular filtration rate and enhanced pressure-induced natriuresis in sp-SHR. Klotho protein bound to AT1R (Ang II type-1 receptor) and decreased the presence of AT1R on HK-2 (human proximal tubular) cells, attenuating inositol triphosphate generation. Klotho protein suppressed Ang II-induced increments of AGT expression in HK-2 cells. Collectively, the present data demonstrate that klotho binds with the AT1R to suppress Ang signal transduction, participating in inactivating renal renin-Ang system. Our results also suggest that exogenous klotho supplementation represses Akt-mTOR signaling to reduce renal hypertrophy and restore the autoregulatory ability of glomerular filtration rate in uninephrectomized sp-SHRs. Finally, the present findings implicate that klotho supplementation inhibits HIF-1α pathway and medullary fibrosis, contributing to enhancements of pressure natriuresis and reduction in blood pressure.

Indexed as

AnimalsBlood PressureFibrosisGlucuronidaseHypertensionKidneyKlotho ProteinsNatriuresisPhosphorylationProto-Oncogene Proteins c-aktRatsRats, Inbred SHRGlucuronidaseKlotho ProteinsProto-Oncogene Proteins c-aktangiotensinogenfibronectinklotho proteinnatriuresisrats

Identifiers

PMID30354813
PMCPMC6247804
OpenAlexW2897457278

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.